<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the present studies we have investigated the effects of a range of glycine site <z:chebi fb="68" ids="48706">antagonists</z:chebi> of the N-<z:chebi fb="36" ids="29309">methyl</z:chebi>-d-<z:chebi fb="0" ids="29995">aspartate</z:chebi> (<z:chebi fb="0" ids="31882">NMDA</z:chebi>) receptor in the gerbil model of global <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The compounds tested were (+)-3-amino-1-hydroxy-2-pyrrolidone (HA 966, 15 mg/kg), 7-chloro-4-hydroxy-3-(3-phenoxy)<z:chebi fb="1" ids="30396">phenyl</z:chebi>-2(H)-quinolinone) (L-701,324, 40 mg/kg), 7-chloro-3-(cyclopropylcarbonyl)-4-hydroxy-2(1H)-quinolinone) (L-701, 252, 50 mg/kg), (3-(3-hydroxyphenyl)prop-2-ynyl 7-chloro-4 hydroxy-2(1H)-<z:chebi fb="1" ids="23765">quinolone</z:chebi>-3-carboxylate) (L-701,273, 50 mg/kg), 5-<z:chebi fb="13" ids="29785">nitro</z:chebi>-6,7-dichloro-2,3-quinoxalinedione (ACEA 1021, 25 mg/kg) and [(E)-3[(phenylcarbamoyl) <z:chebi fb="0" ids="37603">ethenyl</z:chebi>]-4,6-dichloroindole-2-<z:chebi fb="1" ids="33575">carboxylic acid</z:chebi> <z:chebi fb="8" ids="26714">sodium salt</z:chebi> (GV 150526A, 40 mg/kg) </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> compounds were administered via the i.p. route 30 min before and again at 2 h 30 min after 5 min bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> (BCAO) in the gerbil </plain></SENT>
<SENT sid="3" pm="."><plain>For comparison we also evaluated a non-competitive <z:chebi fb="0" ids="31882">NMDA</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi>, (5R,10S)-(+)-5-<z:chebi fb="36" ids="29309">methyl</z:chebi>-10,11-dihydro-5H-dibenzo[a, d]cyclohepten-5,10-<z:chebi fb="0" ids="24783">imine</z:chebi> (MK-801, 2 mg/kg) and an alpha-amino-3-hydroxy-5-methylisoxazole-4-<z:chebi fb="0" ids="30768">propionic acid</z:chebi> (AMPA) <z:chebi fb="68" ids="48706">antagonist</z:chebi>, (3S,4aR, 6R, 8aR)-6-[2-(1(2)H-<z:chebi fb="0" ids="35598">tetrazole</z:chebi>-5-yl)]decahydroisoquinoline-3-car boxylic acid (LY293558, 20 mg/kg) </plain></SENT>
<SENT sid="4" pm="."><plain>In the present studies L-701,252, L-701, 324 and L-701,273 provided a small degree of neuroprotection </plain></SENT>
<SENT sid="5" pm="."><plain>ACEA 1021, GV 150526A and HA 966 failed to provide any neuroprotection, while MK-801 provided significant (20%) protection </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast LY293558 provided good (55%) neuroprotection </plain></SENT>
<SENT sid="7" pm="."><plain>These results indicate that glycine site <z:chebi fb="68" ids="48706">antagonists</z:chebi> and competitive <z:chebi fb="0" ids="31882">NMDA</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> provide a small degree of neuroprotection in global <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, AMPA receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> provide more robust neuroprotection in global <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
</text></document>